nivolumab
Natera, Alliance for Clinical Trials in Oncology Partner for Urothelial Cancer Study
The study will assess the use of Natera's Signatera assay in guiding treatment among people with muscle-invasive urothelial cancer after bladder removal.
Personalis, Ono Pharmaceutical, Japan National Cancer Center Partner on Opdivo Rectal Cancer Trial
In the multicenter VOLTAGE-2 trial, investigators will compare results of the company's tests with standard-of-care measures of drug response.
Agilent PD-L1 Assay Gets FDA Approval as Metastatic NSCLC Companion Diagnostic
Clinicians will be able to use the assay to help identify patients with metastatic NSCLC for treatment with nivolumab and ipilimumab.
The results are of interest to drugmakers looking for scalable technology solutions for assessment of PD-L1 for predicting immunotherapy response.